Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AML With FLT3 Mutation”

98 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 98 results

Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Not applicableNo Longer AvailableNCT03114228
What this trial is testing

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Who this might be right for
FLT3-mutated Acute Myeloid Leukemia
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02400281
What this trial is testing

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Who this might be right for
Acute Myeloid Leukemia
Arog Pharmaceuticals, Inc. 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT05520567
What this trial is testing

Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07726576
What this trial is testing

Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
University Hospital, Bordeaux 41
Early research (Phase 1)Active Not RecruitingNCT05546580
What this trial is testing

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Oryzon Genomics S.A. 50
Early research (Phase 1)Study completedNCT00462761
What this trial is testing

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Who this might be right for
Acute Myeloid LeukemiaLeukemiaMyelodysplastic Syndrome+2 more
Daiichi Sankyo 76
Large-scale testing (Phase 3)Ended earlyNCT02298166
What this trial is testing

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
University of Ulm 9
Large-scale testing (Phase 3)Not Yet RecruitingNCT07425808
What this trial is testing

FLT3-ITD Targeted Therapy in Fit AML Patients

Who this might be right for
AML (Acute Myeloid Leukemia)
European Organisation for Research and Treatment of Cancer - EORTC 230
Early research (Phase 1)Looking for participantsNCT06366789
What this trial is testing

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc. 150
Early research (Phase 1)Looking for participantsNCT07162116
What this trial is testing

Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 45
Large-scale testing (Phase 3)Looking for participantsNCT04293562
What this trial is testing

Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
Children's Oncology Group 1,400
Testing effectiveness (Phase 2)Looking for participantsNCT05010122
What this trial is testing

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center 42
Early research (Phase 1)Looking for participantsNCT06222580
What this trial is testing

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more
Uma Borate 30
Not applicableNo Longer AvailableNCT03409081
What this trial is testing

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Study completedNCT00079482
What this trial is testing

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Cephalon 224
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07755202
What this trial is testing

Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

Who this might be right for
Acute Myeloid LeukemiaAML With FLT3 Mutation
Florian Kuchenbauer 20
Not applicableNo Longer AvailableNCT03746912
What this trial is testing

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
Daiichi Sankyo
Early research (Phase 1)Study completedNCT02323607
What this trial is testing

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Who this might be right for
Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia+1 more
Bhavana Bhatnagar 13
Not applicableStudy completedNCT03047083
What this trial is testing

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Who this might be right for
Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc. 1,027
Next Page